Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy....
Friday, August 24, 2012, 10:38 AM ETOncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles